Processa Pharmaceuticals's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2025 was $-0.30.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.08.
Processa Pharmaceuticals's EPS without NRI for the
three
months ended in Mar. 2025 was $-0.30.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -3.08.
During the past 3 years, the average EPS without NRIGrowth Rate was 35.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 24.00% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 27.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Processa Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 74.20% per year. The lowest was -51.30% per year. And the median was 33.90% per year.
Processa Pharmaceuticals EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Processa Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Processa Pharmaceuticals EPS (Basic) Related Terms
Thank you for viewing the detailed overview of Processa Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCSA has been successfully added to your 